DURHAM, N.C., Aug. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.
A live, audio webcast of Harrington’s presentation will be available through the Investor Relations section of the Oxygen Biotherapeutics, Inc. website. A replay will be available following the event. Webcast login information will be provided on the company website prior to the presentation.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.
Oxygen Biotherapeutics, Inc.
